Deficient Proliferation of Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Chronic Hepatitis B Viral Infections and Cirrhosis of the Liver
Abstract
In this study, we determined whether the proliferation of bone marrow-derived mesenchymal stem cells (MSCs) is impaired in patients with chronic hepatitis B viral infection and cirrhosis of the liver. MSCs from 15 patients with chronic hepatitis B and cirrhosis of the liver (CIR-MSCs) and 11 normal donors (ND-MSCs) were collected and characterized in vitro. CIR-MSCs displayed an intact immunophenotype. The percentage of S-phase nuclei in CIR-MSCs (4.34%), however, was significantly lower than that in ND-MSCs (P < 0.001), indicating impaired proliferation of CIR-MSCs. Growth factor receptor expression (e.g., IGF1, PDGFalpha, and PDGFbeta) on the surface of CIR-MSCs decreased compared to that on ND-MSCs (P < 0.03). We found no evidence that CIR-MSCs were infected with the hepatitis B virus (HBV). Deficient proliferation of CIR-MSCs may result from the decreased expression of growth factor receptors and unbalanced production of cytokines in patients with HBV infection. Our results indicate that autologous MSCs of patients with chronic hepatitis B and cirrhosis of the liver may not be suitable for therapeutic purposes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MSCs derived from older individuals or those with underlying health conditions, such as HBV infection, may exhibit impaired proliferative, differentiation, and regenerative capacities, leading to ineffective treatments or unfavorable clinical outcomes.
“MSCs derived from older individuals or those with underlying health conditions, such as HBV infection, may exhibit impaired proliferative, differentiation, and regenerative capacities, leading to ineffective treatments or unfavorable clinical outcomes [315, 316].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [316]
Cited by
Sorted by citations
Lin, N., Hu, K., Chen, S., Xie, S., Tang, Z., Lin, J., & Xu, R. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.06.007 · Cited by 61 · see citing works
Self-citationEfficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis
Kantarcıoğlu, M., Demirci, H., Avcu, F., Karslıoğlu, Y., Babayiğit, M. A., Karaman, B., Öztürk, K., Gürel, H., Akdoğan Kayhan, M., Kaçar, S., et al. (2015) · Turkish Journal of Gastroenterology · doi:10.5152/tjg.2015.0074 · Cited by 60 · see citing works
Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2 · see citing works
- Authors
- Zhong, Y.-S., Lin, N., Deng, M.-H., Zhang, F.-C., Tang, Z.-F., & Xu, R.-Y.
- Affiliations
- Sun Yat-sen University (CN)
- ORCID
- Lin, Nan
- Venue
- Digestive Diseases and Sciences
- Published
- 2009-02-26
- Volume
- 55
- Issue
- 2
- Pages
- 438-445
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2003613883
- Cited by
- 31
- References
- 0
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 6 · 2014: 2 · 2013: 3 · 2012: 4
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sun Yat-sen University
- Science and Technology Development Fund
- Topics
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- mesenchymal stem cells, chronic hepatitis B, liver cirrhosis, cell proliferation, growth factor receptors, insulin-like growth factor I, platelet-derived growth factor, autologous stem cell therapy, hepatitis B
- MeSH terms
- Adult, Cells, Cultured, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Receptors, Growth Factor, Disease Progression, Hepatitis B, Chronic, Cell Proliferation, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
